Zevra Therapeutics (NASDAQ:ZVRA) Announces Earnings Results

Key Points

• Zevra reported $0.18 EPS for the quarter versus a $0.06 consensus, with robust profitability (ROE 57.4%, net margin 78.2%), and shares jumped about 6% to $11.25 on heavy volume.
• Analysts have an average target of $23 and a consensus rating of "Moderate Buy" (seven Buy, two Hold), indicating elevated expectations versus the current price.
• The company’s pipeline includes lead candidate KP1077 (Phase 2 for idiopathic hypersomnia; Phase 1/2 for narcolepsy) and Celiprolol in Phase 1/2 for vascular Ehlers–Danlos, supporting its development-stage growth thesis.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) released its quarterly earnings results on Wednesday. The company reported $0.18 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.12, FiscalAI reports. Zevra Therapeutics had a return on equity of 57.42% and a net margin of 78.17%.

Zevra Therapeutics Stock Up 6.0%

Shares of NASDAQ:ZVRA traded up $0.64 during trading on Wednesday, hitting $11.25. The stock had a trading volume of 1,886,785 shares, compared to its average volume of 1,019,225. Zevra Therapeutics has a 12 month low of $7.16 and a 12 month high of $13.16. The company has a market capitalization of $665.10 million, a PE ratio of 8.46 and a beta of 0.88. The firm's fifty day moving average is $9.63 and its 200 day moving average is $9.25. The company has a quick ratio of 5.63, a current ratio of 5.68 and a debt-to-equity ratio of 0.40.

Analysts Set New Price Targets

ZVRA has been the subject of several research reports. Guggenheim set a $23.00 target price on Zevra Therapeutics and gave the stock a "buy" rating in a research report on Tuesday, March 10th. BTIG Research initiated coverage on Zevra Therapeutics in a research report on Monday, March 16th. They issued a "buy" rating and a $23.00 target price for the company. Wall Street Zen raised Zevra Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, April 11th. Finally, Weiss Ratings raised Zevra Therapeutics from a "sell (d+)" rating to a "hold (c+)" rating in a research report on Tuesday, March 10th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, Zevra Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $23.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC increased its position in Zevra Therapeutics by 9.6% during the 4th quarter. Millennium Management LLC now owns 1,134,358 shares of the company's stock valued at $10,164,000 after buying an additional 99,107 shares in the last quarter. Man Group plc increased its position in Zevra Therapeutics by 174.4% during the 4th quarter. Man Group plc now owns 92,347 shares of the company's stock valued at $827,000 after buying an additional 58,695 shares in the last quarter. Engineers Gate Manager LP increased its position in Zevra Therapeutics by 23.4% during the 4th quarter. Engineers Gate Manager LP now owns 44,020 shares of the company's stock valued at $394,000 after buying an additional 8,359 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in Zevra Therapeutics during the 4th quarter valued at approximately $124,000. Finally, AQR Capital Management LLC increased its position in Zevra Therapeutics by 18.9% during the 4th quarter. AQR Capital Management LLC now owns 181,129 shares of the company's stock valued at $1,623,000 after buying an additional 28,818 shares in the last quarter. Institutional investors own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.